To investigate if this variant could explains the cisplatin sensitivity of T302 tumours, we used CRISPR/Cas9 to generate RPE-h-TERT TP53-/- cells with a homozygous C1721T mutations (Supplementary Fig. 5) and found that these cells are indeed more sensitive to cisplatin treatment than WT cells (Fig. 5b, c). The gene discussed is TP53; the disease is neoplasm.